The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma

References

• Chakraborty R, Liu HD, Rybicki L, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019;94(4):439–445.
   PubMed Web of Science ®Google Scholar
• Goldman-Mazur S, Visram A, Kapoor P, et al. Outcomes following biochemical or clinical progression in patients with multiple myeloma. Blood Adv. 2022 Apr 12.
   PubMed Web of Science ®Google Scholar
• Bygrave C, Pawlyn C, Davies F, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol. 2021;193(3):551–555.
   PubMed Web of Science ®Google Scholar
• Corre J, Montes L, Martin E, et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105(9):e480–e483.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, et al. Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients With myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(7):445–452.
   PubMed Web of Science ®Google Scholar
• Kumar S, Mahmood ST, Lacy MQ, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008;42(6):413–420.
   PubMed Web of Science ®Google Scholar
• Lee H, Duggan P, Chaudhry A, et al. Early relapse for multiple myeloma patients undergoing single autologous stem cell therapy: a single-center experience. Clin Lymphoma Myeloma Leuk. 2018;18(1):e69–e75.
   PubMed Web of Science ®Google Scholar
• An G, Yan Y, Xu Y, et al. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020;34(2):578–588.
   PubMed Web of Science ®Google Scholar
• Corre J, Cleynen A, du Pont S R, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32(12):2636–2647.
   PubMed Web of Science ®Google Scholar
• Croft J, Ellis S, Sherborne AL, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2021;35(7):2043–2053.
   PubMed Web of Science ®Google Scholar
• Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, et al. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19(4):223–236.
   PubMed Web of Science ®Google Scholar
• Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma. Am J Hematol. 2021;96(7):854–871.
   PubMed Web of Science ®Google Scholar
• Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019;104(7):1440–1450.
   PubMed Web of Science ®Google Scholar
• Misund K, Hofste O, Bruinink D, et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022 Jul;36(7):1887–1897.
   PubMed Web of Science ®Google Scholar
• Shen YJ, Mishima Y, Shi J, et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021;137(17):2360–2372.
   PubMed Web of Science ®Google Scholar
• Yan Y, Qin X, Liu J, et al. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv. 2022;6(2):441–451.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood. 2022;139(19):2889–2903.
   PubMed Web of Science ®Google Scholar
• Hájek R, Delforge M, Raab MS, et al. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol. 2019 Nov;187(4):447–458.
   PubMed Web of Science ®Google Scholar
• Hájek R, Gonzalez-McQuire S, Szabo Z, et al. Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. BMJ Open. 2020 Jul 14;10(7):e034209.
   PubMed Web of Science ®Google Scholar
• Du J, Lu J, Gao W, et al. Serum-free light chains combined with the revised international staging system could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. Ann Hematol. 2020 Aug;99(8):1779–1791. doi:10.1007/s00277-020-04162-8. Epub 2020 Jun 27. PMID: 32594218.
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21.
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022 Oct 10;40(29):3406–3418.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149–157.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Schjesvold F, Doronin V, et al. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized phase 2 trial. Blood Cancer J. 2022 Jan 24;12(1):9.
   PubMed Web of Science ®Google Scholar
• Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137.
   PubMedGoogle Scholar
• Tandon N, Rajkumar SV, LaPlant B, et al. Clinical utility of the revised international staging system in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017;7(2):e528.
   PubMedGoogle Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Huang HC, Shen CI, et al. Post-progression survival in secondary EGFR T790M-mutated non-small-cell lung cancer patients with and without osimertinib after failure of a previous EGFR TKI. Target Oncol. 2020;15(4):503–512.
   PubMed Web of Science ®Google Scholar
• Imai H, Kaira K, Minato K. Clinical significance of post-progression survival in lung cancer. Thorac Cancer. 2017;8(5):379–386.
   PubMed Web of Science ®Google Scholar
• Imai H, Kishikawa T, Minemura H, et al. Post-progression survival influences overall survival among patients with advanced non-small cell lung cancer undergoing first-line pembrolizumab monotherapy. Oncology. 2021;99(9):562–570.
   PubMed Web of Science ®Google Scholar
• Paiva B, Vidriales MB, Rosinol L, et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013;27(10):2056–2061.
   PubMed Web of Science ®Google Scholar
• Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692–1700.
   PubMed Web of Science ®Google Scholar
• Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3(7):e340–e351.
   PubMed Web of Science ®Google Scholar
• Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(8):874–885.
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Gay F, Weisel K, et al. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49:100808.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446–e461.
   PubMed Web of Science ®Google Scholar
• Chavda SJ, Maciocia PM, Mesiri P, et al. A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. Br J Haematol. 2019 Apr;185(2):350–353.
   PubMed Web of Science ®Google Scholar
• D'Agostino M, Zaccaria GM, Ziccheddu B, et al. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020;26(18):4832–4841.
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Law S, Mahmood S, et al. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) amyloidosis. Leukemia. 2022 Apr;36(4):1180–1184.
   PubMed Web of Science ®Google Scholar
• Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835–844.
   PubMed Web of Science ®Google Scholar
• de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022 Sep 1;40(25):2889–2900.
   PubMed Web of Science ®Google Scholar
• Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8(6):e422–e432.
   PubMed Web of Science ®Google Scholar